Bloom X³ contributes to the editorial development and expert review of Morning Glory Sciences (MGS), a specialist publication covering drug discovery and the biopharma industry. MGS has relaunched its website to improve access to its Japanese- and English-language content.
MGS connects FDA approvals, clinical research and scientific developments with questions in drug development, competition, business and investment. Alongside news and contextual analysis, it offers specialist reports for deeper assessment of selected topics.
Bloom X³ brings practical experience in drug discovery, clinical development, business development and investment to this collaboration, helping place information in context and examine its practical implications. The scope of involvement varies by content.
Explore MGS as a resource for understanding developments and identifying the questions that matter next.
Morning Glory Sciences:
https://www.morningglorysciences.com/en/top-page/
Specialist reports:
https://www.morningglorysciences.com/en/restricted-intelligence/
